This might include the counteraction of various arrhythmias [66,67,68,69,70,71,72,73,74,75,76,77,78,80,81,82,102,103,105,106,122,123,154] and thromboses, even blood pressure disturbances (intracranial (superior sagittal sinus), portal and caval hypertension, and aortal hypotension [66,71,72,73,74,75,76,77,78,79,80,81,82], or hypertension (hyperkalemia, NOS-blockade) [67,105] that were attenuated/eliminated peripherally and centrally))
The Phase 3 REDEFINE program in adults with overweight or obesity was subsequently reported in the New England Journal of Medicine in 2025
The 28-day beyond-use date is a USP standard based on bacteriostatic efficacy studies at controlled refrigeration temperatures
BPC-157 and TB-500 are generally discussed in relation to tissue repair